News >

Expert Calls for Clinical Trial Referrals in Molecularly Targetable NSCLC

Angelica Welch
Published: Thursday, Oct 26, 2017

Victoria M. Villaflor, MD

Victoria M. Villaflor, MD
Molecular abnormalities in non–small cell lung cancer (NSCLC) need to be recognized and tested for, explained Victoria M. Villaflor, MD, which means evaluating and referring more patients to clinical trials.

on Advanced Non–Small Cell Lung Cancer, Villaflor, an associate professor of medicine at Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, discussed driver mutations in NSCLC and remaining challenges in treating patients with targetable disease.

OncLive: Can you please provide an overview of your lecture?

Villaflor: Essentially, I spoke about many different molecular driver mutations and translocations that can occur in lung cancer. We covered ALK, ROS1, BRAF V600E, and we talked a little bit about HER2/neu, RET, and NTRK mutations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication